Biomimetic Macrophage Membrane and Lipidated Peptide Hybrid Nanovesicles for Atherosclerosis Therapy

Atherosclerosis is the underlying cause for cardiovascular disease. Current pharmacotherapies are limited by the inadequate targeting and insufficient treatment. Herein, inspired by the interaction of macrophage and lipoprotein as a typical hallmark of atherosclerosis, hybrid nanovesicles (MLP‐NVs)...

Full description

Saved in:
Bibliographic Details
Published in:Advanced functional materials 2022-12, Vol.32 (52), p.n/a
Main Authors: Guo, Linmiao, Miao, Yunqiu, Wang, Ying, Zhang, Ying, Zhou, Erfen, Wang, Jiangyue, Zhao, Yanqi, Li, Lijun, Wang, Aohua, Gan, Yong, Zhang, Xinxin
Format: Article
Language:English
Subjects:
Atherosclerosis
biomimetic nanovesicles
Biomimetics
Cholesterol
comprehensive therapies
Efflux
Endothelial cells
lipidated peptides
macrophage membranes
Materials science
Membranes
Peptides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atherosclerosis is the underlying cause for cardiovascular disease. Current pharmacotherapies are limited by the inadequate targeting and insufficient treatment. Herein, inspired by the interaction of macrophage and lipoprotein as a typical hallmark of atherosclerosis, hybrid nanovesicles (MLP‐NVs) are designed by fusion of anti‐inflammatory M2‐phenotype macrophage membranes and lipidated peptide (DOPE‐pp‐HBSP) to mimic the binding manner of cell‐lipoprotein for atherosclerotic treatment. Through hybridization of M2 macrophage membranes and lipidated peptide film, MLP‐NVs facilitate the inflammatory cell internalization at atherosclerotic site, and sequester the proinflammatory cytokines to suppress local inflammation. Moreover, MLP‐NVs exhibit a matrix metalloprotease 2 (MMP2)‐responsive release of the peptide HBSP in plaques, leading to the restoration of dysfunctional endothelial cells. In the ApoE−/− mice with atherosclerosis, simvastatin‐loaded MLP‐NVs provide comprehensive treatment by inherent inflammation suppression, endothelial repair, and cholesterol efflux capacities, resulting in atherosclerotic plaques regression. Through closely mimicking physiological cues, this biomimetic hybrid nanovesicle platform provides a potential strategy for anti‐atherosclerotic therapy. Biomimetic hybrid nanovesicles (MLP‐NVs) are designed by fusing the M2 macrophage membrane and lipidated peptide, according to the macrophage and lipoprotein binding pattern as a special role in atherosclerosis progress. MLP‐NVs are expected to target plaques and exert anti‐atherosclerotic effects through multiple pathways, including anti‐inflammation, endothelial repair, and cholesterol efflux.
ISSN:1616-301X
1616-3028
DOI:10.1002/adfm.202204822